X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17162) 17162
Newspaper Article (2303) 2303
Newsletter (1016) 1016
Book Chapter (53) 53
Dissertation (46) 46
Magazine Article (33) 33
Book / eBook (17) 17
Publication (15) 15
Trade Publication Article (15) 15
Conference Proceeding (8) 8
Web Resource (4) 4
Government Document (3) 3
Reference (3) 3
Book Review (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
neuroblastoma (13225) 13225
humans (12327) 12327
oncology (6083) 6083
female (4667) 4667
cancer (4616) 4616
male (4421) 4421
neuroblastoma - pathology (3898) 3898
animals (3890) 3890
child (3776) 3776
child, preschool (3310) 3310
neuroblastoma - drug therapy (3280) 3280
cell line, tumor (3211) 3211
pediatrics (3083) 3083
infant (3036) 3036
tumors (3006) 3006
apoptosis (2891) 2891
mice (2602) 2602
chemotherapy (2333) 2333
research (2275) 2275
neuroblastoma - therapy (2161) 2161
neuroblastoma - metabolism (2000) 2000
expression (1993) 1993
prognosis (1902) 1902
adolescent (1896) 1896
neuroblastoma - genetics (1798) 1798
children (1773) 1773
proteins (1610) 1610
cancer therapies (1579) 1579
care and treatment (1405) 1405
gene expression (1398) 1398
cell biology (1368) 1368
adult (1349) 1349
biochemistry & molecular biology (1321) 1321
neurosciences (1320) 1320
metastasis (1317) 1317
surgery (1213) 1213
apoptosis - drug effects (1205) 1205
hematology (1204) 1204
health aspects (1177) 1177
analysis (1176) 1176
therapy (1175) 1175
tumor cells, cultured (1138) 1138
immunotherapy (1009) 1009
combined modality therapy (984) 984
kinases (966) 966
treatment outcome (956) 956
neuroblastoma - diagnosis (952) 952
medicine (945) 945
neoplasm staging (935) 935
genetic aspects (918) 918
medical research (914) 914
infant, newborn (908) 908
antineoplastic agents - pharmacology (892) 892
antineoplastic combined chemotherapy protocols - therapeutic use (884) 884
cells (869) 869
cell survival - drug effects (849) 849
oxidative stress (827) 827
research article (826) 826
diagnosis (823) 823
pharmacology & pharmacy (812) 812
patients (802) 802
antineoplastic agents - therapeutic use (799) 799
differentiation (796) 796
survival (781) 781
medical prognosis (765) 765
neuroblastoma - mortality (765) 765
neuroblastoma - surgery (751) 751
growth (750) 750
mutation (749) 749
dose-response relationship, drug (747) 747
stem cells (745) 745
multidisciplinary sciences (736) 736
retrospective studies (728) 728
signal transduction (728) 728
activation (724) 724
cytotoxicity (724) 724
biology (723) 723
neuroblastoma - radiotherapy (717) 717
neuroblastoma-cells (705) 705
cell cycle (700) 700
middle aged (689) 689
in-vitro (681) 681
nervous system (670) 670
high-risk neuroblastoma (668) 668
neuroblastoma cells (666) 666
rats (666) 666
cell proliferation (659) 659
risk factors (644) 644
cell proliferation - drug effects (640) 640
pathology (638) 638
development and progression (632) 632
studies (632) 632
medicine & public health (631) 631
time factors (630) 630
mice, nude (628) 628
gene expression regulation, neoplastic (624) 624
science (605) 605
phosphorylation (603) 603
genes (602) 602
immunology (600) 600
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19930) 19930
German (225) 225
Japanese (183) 183
French (170) 170
Italian (71) 71
Spanish (63) 63
Polish (54) 54
Russian (54) 54
Chinese (39) 39
Czech (13) 13
Dutch (12) 12
Portuguese (8) 8
Danish (7) 7
Turkish (7) 7
Korean (6) 6
Norwegian (5) 5
Hungarian (4) 4
Swedish (4) 4
Hebrew (3) 3
Romanian (3) 3
Serbian (2) 2
Catalan (1) 1
Croatian (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2010, Volume 363, Issue 14, pp. 1324 - 1334
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 83, Issue 3, pp. 1015 - 1022
Purpose To report the early outcomes for children with high-risk neuroblastoma treated with proton radiotherapy (RT... 
Radiology | Hematology, Oncology and Palliative Medicine | High-risk neuroblastoma | IMPT | Intensity-modulated radiotherapy | Proton radiotherapy | IMRT | Intensity-modulated proton radiotherapy | SURVIVAL | RADIATION-THERAPY | TRANSPLANTATION | IMPACT | ONCOLOGY | INFANTS | LOCAL-CONTROL | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | RESEARCH-HOSPITAL EXPERIENCE | Protons - adverse effects | Humans | Child, Preschool | Protons - therapeutic use | Infant | Male | Neuroblastoma - therapy | Organs at Risk | Radiotherapy, Intensity-Modulated - adverse effects | Neoplasm, Residual | Organ Sparing Treatments - methods | Female | Neuroblastoma - pathology | Radiotherapy Dosage | Neuroblastoma - genetics | Radiotherapy, Intensity-Modulated - methods | Induction Chemotherapy - methods | Neuroblastoma - diagnostic imaging | Treatment Outcome | Tumor Burden | Combined Modality Therapy - adverse effects | Photons - therapeutic use | Radiography | Neuroblastoma - radiotherapy | Radiotherapy, Conformal - adverse effects | Combined Modality Therapy - methods | Radiotherapy, Conformal - methods | Pediatrics | Neuroblastoma | Radiotherapy | Nuclear radiation | Analysis | Radiation | Adjuvants | SURGERY | PATIENTS | NEOPLASMS | FAILURES | LUNGS | ERYTHEMA | RADIATION DOSES | PROTONS | CHEMOTHERAPY | CHILDREN | HEART | KIDNEYS | RADIATION DOSE DISTRIBUTIONS | RADIOLOGY AND NUCLEAR MEDICINE | PEDIATRICS | STEM CELLS | RADIOTHERAPY | SKIN | SIDE EFFECTS | ANOREXIA | HAZARDS
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 2013, Volume 85, Issue 3, pp. e151 - e155
Journal Article
Annals of oncology, ISSN 0923-7534, 2007, Volume 18, Issue 11, pp. 1782 - 1792
In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged... 
Radionuclide therapy | Transarterial radionuclide therapy | Radiopharmaceuticals | Peptide receptor radionuclide therapy | Radioiodine therapy | Radio immunotherapy | MURINE MONOCLONAL-ANTIBODY | I-131 METAIODOBENZYLGUANIDINE | radioimmunotherapy | peptide receptor radionuclide therapy | DIFFERENTIATED THYROID-CARCINOMA | CARCINOEMBRYONIC-ANTIGEN RADIOIMMUNOTHERAPY | radiopharmaceuticals | RANDOMIZED CONTROLLED TRIAL | radioiodine therapy | PHASE-II TRIAL | HEPATOCELLULAR-CARCINOMA | radionuclide therapy | ONCOLOGY | HIGH-DOSE I-131-METAIODOBENZYLGUANIDINE | REFRACTORY LOW-GRADE | RECEPTOR RADIONUCLIDE THERAPY | transarterial radionuclide therapy | Thyroid Neoplasms - diagnosis | Prognosis | Hematologic Neoplasms - mortality | Humans | Male | Neuroblastoma - mortality | Ovarian Neoplasms - mortality | Ovarian Neoplasms - radiotherapy | Nuclear Medicine - trends | Hematologic Neoplasms - radiotherapy | Ovarian Neoplasms - diagnostic imaging | Female | Neoplasms - radiotherapy | Nuclear Medicine - standards | Thyroid Neoplasms - mortality | Hematologic Neoplasms - diagnostic imaging | Risk Assessment | Neoplasms - mortality | Neuroblastoma - diagnostic imaging | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Neoplasms - diagnostic imaging | Forecasting | Neuroblastoma - radiotherapy | Radionuclide Imaging | Survival Analysis | 3-Iodobenzylguanidine - therapeutic use | Indium Radioisotopes - therapeutic use | Radiopharmaceuticals - therapeutic use | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
CURRENT MEDICINAL CHEMISTRY, ISSN 0929-8673, 2017, Volume 24, Issue 15, pp. 1488 - 1503
DNA-damaging drugs in cancer present two main problems: therapeutic resistance and side effects and both can associate with DNA repair, which can be targeted in cancer therapy. Bleomycin (BLM... 
bleomycin | mitomycin C | CHEMISTRY, MEDICINAL | TOPOISOMERASE-II | DNA quadruplex | SMALL-MOLECULE | BIOCHEMISTRY & MOLECULAR BIOLOGY | synthetic lethality | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | DNA repair | FANCONI-ANEMIA | TUMOR-INITIATING CELLS | CANCER STEM-CELLS | DNA-damaging drugs | PHARMACOLOGY & PHARMACY | DNA topoisomerase 1 and 2 inhibitors | HUMAN RECQ HELICASES | HIGH-RISK NEUROBLASTOMA | RNA G-QUADRUPLEX | DNA Damage - drug effects | Antibiotics, Antineoplastic - toxicity | G-Quadruplexes - drug effects | Phosphoric Diester Hydrolases - metabolism | Topoisomerase Inhibitors - toxicity | Humans | DNA Topoisomerases - metabolism | DNA Topoisomerases - chemistry | Neoplasms - drug therapy | Phosphoric Diester Hydrolases - chemistry | Topoisomerase Inhibitors - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Bleomycin - therapeutic use | DNA Repair | Topoisomerase Inhibitors - chemistry | Neoplasms - pathology | Bleomycin - toxicity | Cell proliferation | Drugs | Therapy | Protein kinase C | Toxicity | Stabilization | DNA damage | Poly(ADP-ribose) | Xeroderma pigmentosum | Lethality | Kinases | Guanine | Proteins | Antitumor agents | Bleomycin | Pathways | Ribose | Mitomycin C | Catalysis | Repair | Telomerase | Deoxyribonucleic acid--DNA | Adducts | Phosphodiesterase | Mitomycin | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Nucleotide excision repair | Crosslinking | Substrates | Telomeres | Poly(ADP-ribose) Polymerase 1 | Side effects | DNA-dependent protein kinase | DNA adducts | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 67, pp. 130 - 140
... at enrolment in their first dose-finding trial between 2000 and 2014 at eight centres of the Innovative Therapies for Children with Cancer European consortium were collected... 
Hematology, Oncology and Palliative Medicine | Innovative Therapies for Children with Cancer | Dose-finding trial | Prognostic factor | Phase I trial | Children | Adolescents | Survival | ONCOLOGY TRIALS | SCORE | VALIDATION | I CLINICAL-TRIALS | CONTEXT | PEDIATRIC PHASE-I | CENTER EXPERIENCE | ONCOLOGY | Osteosarcoma - drug therapy | Multivariate Analysis | Prognosis | Neuroectodermal Tumors, Primitive - drug therapy | Humans | Child, Preschool | Infant | Male | Neuroblastoma - mortality | Sarcoma, Ewing - mortality | Medulloblastoma - mortality | Ependymoma - drug therapy | Employment | Ependymoma - mortality | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Retrospective Studies | Child | Rhabdomyosarcoma - mortality | Schools | Osteosarcoma - mortality | Glioma - mortality | Neuroectodermal Tumors, Primitive - mortality | Europe | Proportional Hazards Models | Neoplasms - mortality | Therapies, Investigational | Survival Rate | Sarcoma - drug therapy | Neoplasms - drug therapy | Sarcoma, Ewing - drug therapy | Neuroblastoma - drug therapy | Adolescent | Medulloblastoma - drug therapy | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Clinical Trials, Phase I as Topic | Glioma - drug therapy | Care and treatment | Patient outcomes | Children's hospitals | Oncology, Experimental | Clinical trials | Research | Health aspects | Cancer
Journal Article
Nature medicine, ISSN 1546-170X, 2018, Volume 24, Issue 10, pp. 1545 - 1549
Journal Article